Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05453799 · ClinicalTrials.gov registry record · Phase 2
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
A Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Thyroid Gland Anaplastic Carcinoma, sponsored by Northwestern University.
- Active
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 2
- Study locations
NCT05453799: Active Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Thyroid Gland Anaplastic Carcinoma, sponsored by Northwestern University.
NCT05453799 is a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Thyroid Gland Anaplastic Carcinoma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 54 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05453799, a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Thyroid Gland Anaplastic Carcinoma, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as vudalimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- DRUG Vudalimab
Study Locations (2)
Illinois
- Northwestern University - Chicago
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 2 |
What the registry record for NCT05453799 still lists
NCT05453799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 3 conditions, with Metastatic Thyroid Gland Oncocytic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Vudalimab is the first listed.
NCT05453799 reports a single indexed study location in Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT05453799 about?
NCT05453799 is a clinical study titled "Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer". This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibo...
What is the current status of trial NCT05453799?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2022-07-21. Estimated completion is 2027-07-15.
What conditions does trial NCT05453799 study?
This clinical trial studies the following conditions: Metastatic Thyroid Gland Oncocytic Carcinoma, Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma.
What interventions are being tested in trial NCT05453799?
The interventions under investigation include: Vudalimab (DRUG).
Who is sponsoring clinical trial NCT05453799?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05453799 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Thyroid Gland Oncocytic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05453799's enrollment target sits among peer trials
54 1160th of 2000 higher than 830 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI